Merkel Cell Carcinoma Market: Epidemiology, Therapies, Companies, DelveInsight | Amgen Inc., Pfizer Inc., BeiGene, OncoSec Medical Incorporated, Immune Design, Merck Sharp & Dohme LLC, Immunomic Therapeutics, Inc., Incyte Corporation, Kartos Therapeutics,

Merkel Cell Carcinoma therapies, such as Pembrolizumab (MK-3475), ITI-3000, Retifanlimab, KRT-232, Nivolumab, Avelumab, atezolizumab,, and others, are expected to boost the Merkel Cell Carcinoma Market in the upcoming years.

DelveInsight has launched a new report on "Merkel Cell Carcinoma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Merkel Cell Carcinoma, historical and forecasted epidemiology as well as the Merkel Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Merkel Cell Carcinoma market report @ https://www.delveinsight.com/report-store/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Merkel Cell Carcinoma Market Report:

The Merkel Cell Carcinoma (MCC) market is expected to experience consistent growth, with a notable compound annual growth rate (CAGR) forecasted from 2024 to 2034. This expansion across the 7 major markets (7MM) will be fueled by the introduction of novel therapies, including IFx-2.0, NIDLEGY, and ITI-3000.
In June 2025, the FDA removed a manufacturing-related partial clinical hold on TuHURA Biosciences' IFx‐2.0 Phase III trial (NCT06947928) for advanced/metastatic MCC. This allows initiation of clinical sites and enrollment of approximately 118 patients in the U.S. to investigate IFx‐2.0 combined with pembrolizumab versus pembrolizumab alone
DelveInsight estimates that in 2023, there were around 9,000 new cases of Merkel Cell Carcinoma in the 7MM. The United States accounted for approximately 37% of these cases, while the EU4 and the UK made up about 61%, and Japan represented around 2%.
In terms of market size, DelveInsight reports that the Merkel Cell Carcinoma treatment market in the 7MM was valued at roughly USD 411 million in 2023. Over the 2024-2034 forecast period, the market is expected to grow at a CAGR of 8.7%.
Key companies operating in the Merkel Cell Carcinoma treatment space include Merck KGaA, Incyte Corporation/MacroGenics, and Merck & Co. Notable approved therapies in this market are **BAVENCIO** (available in the US, EU4, UK, and Japan), **ZYNYZ** (approved in the US, EU4, and UK), and **KEYTRUDA** (approved in the US).
In 2023, the United States recorded the highest number of new Merkel Cell Carcinoma cases, with around 3,000 reported. This number is projected to grow at a compound annual growth rate (CAGR) of 5% through 2034.
Among the EU4 and the UK, Germany had the highest incidence of Merkel Cell Carcinoma in 2023, with approximately 1,700 cases, followed by France with around 1,300 cases. Spain reported the fewest new cases, totaling roughly 600.
Treatment of MCC in elderly patients poses challenges due to the presence of comorbidities, which can hinder therapeutic efficacy and negatively impact outcomes.
Promising Merkel Cell Carcinoma therapies include Pembrolizumab (MK-3475), ITI-3000, Retifanlimab, KRT-232, Nivolumab, Avelumab, atezolizumab,, and others.

Merkel Cell Carcinoma Overview

Merkel Cell Carcinoma (MCC) is a rare and aggressive form of neuroendocrine skin cancer that originates from Merkel cells-specialized touch-sensitive cells located at the dermo-epidermal junction. Due to its rapid growth and early tendency to spread, MCC ranks among the most lethal skin cancers, highlighting the unique role of Merkel cells in both sensory function and malignancy.
MCC is classified based on the involvement of the Merkel Cell Polyomavirus (MCPyV). Virus-positive MCC results from the integration of MCPyV DNA into the host genome, leading to tumor development through viral oncoproteins. These tumors typically have a lower mutation burden but respond more favorably to immunotherapy. In contrast, virus-negative MCC is driven by ultraviolet (UV) radiation and characterized by a higher rate of genetic mutations, greater aggressiveness, and poorer clinical outcomes.
Sun exposure is a major risk factor, particularly in older adults and immunocompromised individuals, such as organ transplant recipients or those with chronic lymphocytic leukemia (CLL) or HIV. MCC most often develops on sun-exposed areas like the head and neck.
The two main subtypes of MCC are:
MCPyV-positive, associated with viral oncoproteins that disrupt tumor suppressors like RB1 and p53.

MCPyV-negative, linked to UV-induced DNA damage and marked by a high mutational burden.

Merkel Cell Carcinoma Market Outlook

Merkel Cell Carcinoma (MCC) is marked by its aggressive nature, with rapid tumor growth, a high likelihood of metastasis, and poor prognosis, particularly in advanced stages. Treatment approaches vary depending on the stage of the disease and patient-specific factors. For localized MCC, surgery combined with radiation remains the standard of care, while systemic treatments-especially immunotherapy-have significantly improved outcomes in advanced cases.
Localized MCC is generally managed with wide local excision, often paired with radiation therapy. A sentinel lymph node biopsy is commonly performed to assess regional spread. In later stages, surgical interventions become less effective due to widespread disease, emphasizing the urgent need for more effective therapies, especially given MCC's rarity and high recurrence rate.
Systemic therapies such as immune checkpoint inhibitors have revolutionized the treatment of advanced MCC. Avelumab (BAVENCIO), pembrolizumab (KEYTRUDA), and retifanlimab-dlwr (ZYNYZ) are among the leading FDA-approved immunotherapies targeting PD-1 or PD-L1 pathways, enhancing the body's immune response to cancer.
In contrast, chemotherapy-which once played a central role in managing metastatic MCC-now has a limited role. Agents like etoposide and carboplatin can temporarily shrink tumors, but they offer minimal long-term benefits and are associated with high relapse rates and significant side effects. Cytotoxic chemotherapy acts by targeting rapidly dividing cells, but its lack of selectivity often results in damage to healthy tissues, limiting its sustained effectiveness in MCC management.

Merkel Cell Carcinoma Market Insights

The primary treatment for Merkel Cell Carcinoma typically begins with surgery, often followed by radiation or chemotherapy, especially in cases where the tumor does not respond sufficiently to surgery alone. For advanced or metastatic disease, immunotherapy-particularly PD-1/PD-L1 inhibitors-is used to stimulate the immune system to fight the cancer more effectively.

Several innovative therapies are currently under development for Merkel Cell Carcinoma. These include:

* **IFx-2.0**, developed by TuHURA Biosciences, which works by activating the immune system to attack cancer cells. A Phase III trial in combination with KEYTRUDA is planned for 2025 to treat advanced cases.
* **NIDLEGY** (a combination of L19-IL2 and L19-TNF), developed by Philogen, enhances immune activity and directly targets tumor tissues. It is showing promise as a targeted immunotherapy for Merkel Cell Carcinoma.
* **MCLA-145**, a next-generation T-cell agonist that targets both PD-L1 and CD137, aims to enhance immune responses against tumors. It is currently being evaluated in Phase I trials alongside pembrolizumab.

Discover how the Merkel Cell Carcinoma market is rising in the coming years @ https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Marketed Merkel Cell Carcinoma Drugs
BAVENCIO (avelumab): Merck KGaA
ZYNYZ (retifanlimab-dlwr): Incyte Corporation/MacroGenics
KEYTRUDA (pembrolizumab): Merck
Merkel Cell Carcinoma Emerging Drugs
IFx-2.0: TuHURA Biosciences
NIDLEGY (L19-IL2/L19-TNF): Philogen
MCLA 145: Merus N.V.

Scope of the Merkel Cell Carcinoma Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Merkel Cell Carcinoma Companies: Amgen Inc., Pfizer Inc., BeiGene, OncoSec Medical Incorporated, Immune Design, Merck Sharp & Dohme LLC, Immunomic Therapeutics, Inc., Incyte Corporation, Kartos Therapeutics, Inc., Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center, Immune Oncology, and others
Merkel Cell Carcinoma Therapies: Pembrolizumab (MK-3475), ITI-3000, Retifanlimab, KRT-232, Nivolumab, Avelumab, atezolizumab,, and others.
Merkel Cell Carcinoma Therapeutic Assessment: Merkel Cell Carcinoma current marketed and Merkel Cell Carcinoma emerging therapies
Merkel Cell Carcinoma Market Dynamics: Merkel Cell Carcinoma market drivers and Merkel Cell Carcinoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Merkel Cell Carcinoma Unmet Needs, KOL's views, Analyst's views, Merkel Cell Carcinoma Market Access and Reimbursement

To know what's more in our Merkel Cell Carcinoma report, visit https://www.delveinsight.com/report-store/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Merkel Cell Carcinoma Market Report:
The Merkel Cell Carcinoma market report covers a descriptive overview and comprehensive insight of the Merkel Cell Carcinoma Epidemiology and Merkel Cell Carcinoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Merkel Cell Carcinoma market report provides insights into the current and emerging therapies.
The Merkel Cell Carcinoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Merkel Cell Carcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Merkel Cell Carcinoma market.

Got queries? Click here to know more about the Merkel Cell Carcinoma market Landscape https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Merkel Cell Carcinoma Patient Share (%) Overview at a Glance
5. Merkel Cell Carcinoma Market Overview at a Glance
6. Merkel Cell Carcinoma Disease Background and Overview
7. Merkel Cell Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Merkel Cell Carcinoma
9. Merkel Cell Carcinoma Current Treatment and Medical Practices
10. Unmet Needs
11. Merkel Cell Carcinoma Emerging Therapies
12. Merkel Cell Carcinoma Market Outlook
13. Country-Wise Merkel Cell Carcinoma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Merkel Cell Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Merkel Cell Carcinoma Market Outlook 2034 https://www.delveinsight.com/report-store/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Merkel Cell Carcinoma Pipeline Insights, DelveInsight

"Merkel Cell Carcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Merkel Cell Carcinoma market. A detailed picture of the Merkel Cell Carcinoma pipeline landscape is provided, which includes the disease overview and Merkel Cell Carcinoma treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.